Defeat Duchenne Canada is pleased to announce that regulatory authorities in Canada, along with the U.S., United Kingdom, Taiwan, Spain, and Belgium have approved the re-start of the Pfizer Phase 3 ambulatory trial (CIFFREO) for their investigational mini-dystrophin gene therapy for Duchenne muscular dystrophy. The timing on the re-start of the trials in Canada will be shared as soon as that information is available.

Click the button below to read the letter from Pfizer for the Duchenne community.